News & Events
Crinetics Pharmaceuticals Awarded NIH Fast-Track Grant to Develop Somatostatin Receptor Agonist Drugs for Chronic Pain
SAN DIEGO – April 27, 2015 – Crinetics Pharmaceuticals (“Crinetics”), an innovative therapeutics company focused on endocrine diseases and cancers, announced today that it has been awarded Phase I of a Fast-Track Small Business Innovation Research (SBIR) grant of up to $2. 7MM from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH) for the development of orally-available, small molecule somatostatin receptor agonist drugs for the treatment of chronic and neuropathic pain disorders.
READ MORECrinetics Pharmaceuticals Awarded $1.5MM NIH Phase-II SBIR Grant to Develop Kisspeptin Receptor Antagonists for PCOS and Other Women’s Health Diseases
SAN DIEGO — January 28, 2015 — San Diego-based Crinetics Pharmaceuticals announced today that it has been awarded a $1. 5 MM Phase II Small Business Innovation Research (SBIR) grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) of the National Institutes of Health (NIH) for the development of orally-available, small molecule kisspeptin receptor antagonists to treat polycystic ovary syndrome (PCOS) and other women’s health disorders. “PCOS is so prevalent, yet inadequately treated in most patients.
READ MORECrinetics Pharmaceuticals Awarded NIH Phase-I SBIR Grant to Develop Somatostatin Receptor Agonist Drugs for Ophthalmic Diseases
SAN DIEGO — April 28, 2014 — San Diego-based Crinetics Pharmaceuticals announced today that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Eye Institute (NEI) of the National Institutes of Health (NIH) to explore the use of its oral, small molecule somatostatin receptor agonist drug candidates for the treatment of ophthalmic diseases such as macular degeneration and diabetic retinopathy. Currently, it is estimated that 11 million Americans suffer from age-related macular degeneration (AMD) – this number is expected to double in the next generation. Worldwide, the global diabetes epidemic has pushed the number of people suffering from diabetic retinopathy to an estimated 93 million.
READ MORECrinetics Pharmaceuticals Awarded NIH Phase-II SBIR Grant to Develop Drugs for Pituitary Tumors
SAN DIEGO — September 3, 2013 — San Diego-based Crinetics Pharmaceuticals announced today that it has been awarded a $2. 2MM Phase II Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to develop novel drugs for the treatment of pituitary tumors. These tumors produce excess growth hormone resulting in a range of symptoms that can include gigantism, excess soft tissue growth, arthritis, hypertension, diabetes, heart failure, kidney failure, and vision loss, a condition called acromegaly.
READ MORECrinetics Pharmaceuticals Awarded National Institutes of Health Small Business Innovative Research Grant to Develop GPCR Biosensors for Drug Discovery
Crinetics Pharmaceuticals announced today that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to develop G protein-coupled receptor (GPCR) biosensors for drug discovery applications. The grant supports the Company’s effort to expand this cutting-edge research tool to drug targets addressing important unmet medical needs and adapt the technology to formats suitable for routine use in GPCR drug discovery. GPCR biosensors are one component of the company’s emerging GPCR Dynamics assay platform.
READ MORE- « Previous
- 1
- …
- 31
- 32
- 33
Transforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine-rooted care.
Email Signup
Please click CONTINUE below to learn more about a new treatment option. This website contains information about a prescription medicine.
